Milestones in Advanced Bladder Cancer
Episode description
Podcast Host Disclosures:
Dr. Alimohamed has had a consulting or advisory role with Astellas Pharma, AstraZeneca, Janssen, Merck, Pfizer, and Sanofi Canada.
Dr. Lalani has received honoraria from Astellas Pharma, Bayer, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche/Genentech, and TerSera; has had a consulting or advisory role with Abbvie, Astellas Pharma, Bayer, Bristol-Myers Squibb, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche/Genentech, and TerSera; and has received research funding from Bristol-Myers Squibb (Inst), Ipsen, Novartis, and Roche.
Accreditation:
This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits.
Obtain Section 3 Credits Here >
References:
Bellmunt J, et al. Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. J Clin Oncol. 2021;39(suppl 15): abstr 4532. https://bit.ly/3axehzb
Loriot Y, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338-348. https://www.nejm.org/doi/full/10.1056/NEJMoa1817323
O’Donnell PH, et al. First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study. J Clin Oncol. 2021;39(suppl 15): abstr 4508. https://bit.ly/3gyklv5
Powles T, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230. https://www.nejm.org/doi/full/10.1056/NEJMoa2002788
Powles T, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125-1135. https://www.nejm.org/doi/full/10.1056/NEJMoa2035807